In a quiet imaging suite, fifteen volunteers surrendered their ordinary minds to LSD and returned with data that reframes how we understand consciousness itself. Researchers at the Universities of Pavia and Florence found that the drug does not amplify the brain so much as it unravels its local order — silencing the synchronized rhythms that keep neighboring neurons in step, and in doing so, dissolving the hierarchical boundaries that normally separate sight from touch, self from world. The discovery suggests that what we call an altered state of consciousness may be less a matter of more brai
PsyPost
· Jul 18, 2026
· health
· 5 min de leitura
Medium
Apuração: Verificado
Brain scans show LSD fragments local neural activity to reshape consciousness
◉
Health & Medicine
6220 artigos relacionados
Mix-and-match COVID boosters offer immune system flexibility, expert e…
The Conversation · 100% correspondência
FDA poised to approve scaled COVID vaccine for children ages 5-11
Futurity: Research News · 99% correspondência
Context matters: Why vaccinated people dominate COVID hospital numbers
The Canberra Times · 99% correspondência
Pharma M&A Surge Amid Drug Price Scrutiny, Bird Flu Vaccination Push
Devdiscourse · 99% correspondência
Global health agencies mobilize against mpox, COVID variants amid bird…
Devdiscourse · 99% correspondência
Cobertura Relacionada
The New York Times · Jul 21
Why Epidemics Trigger Rage Against Health Care Workers
The New York Times examines why societies repeatedly direct hostility toward healthcare workers during epidemic outbreak…
News-Medical · Jul 21 Study finds no link between sleep chronotype and liver disease markersItalian researchers found no significant association between chronotype and liver fat or fibrosis in 119 adults with obe…
DD India · Jul 21 India Approves First Dengue Vaccine Qdenga for Ages 4-60India's drug regulator CDSCO has approved Qdenga, the country's first dengue vaccine, for ages 4-60. The Takeda-develope…
insightnews.com.au · Jul 21 Optical Dispenser's 28-Year Journey: Why Being Yourself Is Your SuperpowerSonya Broadhead, a 28-year optical industry veteran and co-owner of See Side Optical, reflects on her career evolution f…
Viés e Enquadramento
⚖
Article presents neuroscience findings on LSD's brain effects with neutral, scientific framing and balanced discussion of therapeutic potential without advocacy.
Bias Direction
center
Confidence
HIGH
Scientific objectivity framing - presents research findings using technical language, attributes claims to peer-reviewed sources, and contextualizes within broader medical research trends without editorial judgment.
mind-altering effects
profound changes in perception
hallucinogenic drug
Regulatory or policy perspectives on psychedelic research
Voices from addiction medicine or harm reduction specialists
Ethical considerations regarding human subjects in psychedelic research
Counterarguments or skeptical scientific viewpoints on therapeutic claims
Impacto Geopolítico
🌎
This is a neuroscience article about LSD's effects on brain activity, not a geopolitical event. No international implications exist.
Escalation Risk
N/A
Confidence
HIGH
N/A - This article concerns neuroscience research, not geopolitics, international relations, or power dynamics between nations or actors.
Lente Econômica
📈
LSD research advances understanding of psychedelic mechanisms through neuroscience, potentially enabling therapeutic psychiatric treatments and creating future biotech/pharmaceutical opportunities.
Market Signal
bullish
Confidence
MED
Pharmaceutical and Biotech
Mental Health and Healthcare Services
Medical Research and Diagnostics
Neuroimaging Technology
Consumers may eventually benefit from new psychiatric treatments for depression, anxiety, and PTSD if psychedelic-based therapies advance through clinical trials. Healthcare costs could decrease if effective alternatives to current medications emerge.
Regulatory agencies (FDA, EMA) may accelerate approval pathways for psychedelic-assisted therapies. Drug scheduling policies could shift as clinical evidence accumulates. Research funding and clinical trial frameworks will likely expand. Insurance coverage discussions will emerge as treatments move toward commercialization.